No evidence of distant metastases
Patients with evidence of distant metastases or leptomeningeal disease (LMD) are excluded
No evidence of distant metastases
Patients must have no clinical or radiological evidence of distant metastases (M)
Presence of distant metastatic disease
Distant metastases
Patients with distant metastatic disease
Have evidence of a distant metastatic disease
No evidence of local recurrence or distant metastases
Patients cannot have distant metastases and have to be candidates for curative re-irradiation
Patients with distant metastatic disease or otherwise not confined to the ipsilateral hemithorax
Radiographic evidence of regional or distant metastases with suspected tumor in an area that is safe to biopsy
Evidence of distant metastases of stage IV
Documented evidence of distant metastases
No evidence of in-transit, nodal or distant metastases as determined by clinical examination, CT or MRI
Prostate cancer:\r\n* Distant metastases\r\n* Lymph node metastases
Presence of distant metastatic disease
Documented evidence of distant metastases
Patients with distant metastatic disease (prostate adjacent adenopathy is not an exclusion)
Distant metastases (M disease)
Unequivocal demonstration of distant metastases (M disease)
Evidence of distant metastases as determined by the central reading committee
Evidence of distant metastatic disease
Unresectable primary tumor or regional disease or distant metastases
Stage  or  disease without evidence of distant metastases
Clinical or pathologic evidence for distant metastases
Clinical or pathologic evidence for distant metastases
Documented distant metastatic disease
Documented evidence of distant metastases
Evidence of distant metastases
No evidence of distant metastases
Evidence of distant metastases on any staging or imaging modality
Patients with distant organ metastases will not be included in this study
For patients undergoing definitive CFRT, patients with distant metastatic disease are not eligible
Patients with any evidence of distant metastases
Distant metastatic disease
Distant metastases
Evidence of distant metastases
MAIN STUDY COHORT EXCLUSION CRITERIA: Evidence of nodal or distant metastases
Presence of distant metastatic (M) disease
Evidence of distant metastases
No evidence of distant metastases
Presence of distant metastatic disease
The patients have documented disease beyond the peritoneal surfaces, which prevent achieving complete cytoreduction as indicated by:\r\n* Evidence of distant hematogenous metastatic disease or distant nodal metastases\r\n* Evidence of parenchymal hepatic metastases\r\n* Evidence of clinical, biochemical or radiological biliary obstruction\r\n* Evidence of gross disease of the small bowel mesentery characterized by distortion, thickening or loss of mesenteric vascular clarity which limits ability to obtain complete cytoreduction
Evidence of distant metastases
No evidence of distant metastatic disease
Clinical evidence of regional, intransit ,or distant metastases
No known local regional or distant metastatic disease
Documented evidence of distant metastases
Evidence of distant metastases or distant leptomeningeal metastases at the time of diagnosis
Evidence of distant metastases
Evidence of distant metastases (excluding para-aortic nodes)
Patient with distant metastases
History and/or clinical evidence of distant metastases (M)
Evidence of distant metastases (below the clavicle) by clinical or radiographic measures.
Stage  or  disease without evidence of distant metastases
No evidence of distant metastases
No evidence of distant metastases and measurable disease (> . cm).
Patients with any evidence of distant metastases
Has known distant metastases; clinically involved pelvic nodes (N-N) are allowed
No evidence of distant metastatic disease
Clinical evidence of local recurrence or distant metastases; Note: all patients must have either a positron emission tomography (PET)/computed tomography (CT) or a CT of chest, abdomen and pelvis and a bone scan; if one or more of these is concerning for distant metastases, follow-up imaging and/or biopsy should be performed to rule out distant metastases prior to randomization
Patients with distant bone metastases at original diagnosis or relapse (patients with only skip lesions will be eligible)
Distant metastases
Evidence of distant metastatic disease (i.e. lung, liver, bone, brain, etc.)
Evidence of distant metastases or histologically or cytologically proven lymph node metastases
Distant metastases
Patients with known distant metastases
Documented evidence of distant metastases
Evidence of distant metastases
Patients are eligible for this trial either at initial presentation of their melanoma or at the time of the first detected nodal, satellite/in-transit, distant metastases, or recurrent disease in prior lymphadenectomy basin or distant site; nodal, satellite/in-transit metastasis, distant metastases or disease in a prior complete lymphadenectomy basin must have been confirmed histologically by hematoxylin and eosin (H & E) stained slides
Distant metastases (stage IV C, any T, any N and M)
Evidence of distant metastatic disease
Evidence of distant metastases (M)
Clinical evidence of distant metastases per practice guidelines for breast cancer;
Evidence of distant metastatic disease (Masaoka stage IVB)
Isolated, distant, or non-contiguous intra-abdominal metastases, even if resected.
No indication of distant metastases
Distant metastases (M disease).
No direct evidence of regional or distant metastases after appropriate staging studies;
Presence of distant metastases
Documented distant metastatic disease; NOTE: pelvic lymphadenopathy is NOT excluded
Patient has evidence of distant metastases
History or current radiographic or pathologic evidence of distant metastases
Documented distant metastatic disease
Evidence of distant metastases or histologically or cytologically proven lymph node metastases
Any distant metastatic disease
Physical, clinical, radiographic or pathologic evidence of satellite, in-transit, regional, or distant metastatic melanoma.
Distant metastatic disease, including known brain metastases
Any evidence of distant metastases (M)
Unequivocal demonstration of distant metastases (M disease)
Patients with distant metastatic disease (Mc) will not be eligible for this study
Distant metastatic disease not limited to peritoneum: solid organ metastases (liver, central nervous system, lung)
Any distant metastatic disease visualized on preoperative imaging:\r\n* Solid organ metastases\r\n* Clear radiologic evidence of carcinomatosis
No distant metastases
Tumors considered to be unresectable due to local advancement include an absence of distant metastases as well as:
Stage  or  disease without evidence of distant metastases
Patient must not have known distant metastatic disease at presentation
Evidence of distant metastatic disease.
Patients with clinical, radiological/laboratory, or pathological evidence of distant metastatic disease
Documented distant metastatic disease; but pelvic lymphoadenopathy is NOT excluded
Radiographic evidence of regional or distant metastases with suspected tumor in an area that is safe to biopsy
Patients who require radiotherapy to distant metastases during induction systemic therapy are eligible
Distant metastases, including CNS and vertebral or meningeal involvement
Patients with distant metastases
The participant has confirmed HR+, HER-, early stage resected invasive breast cancer without evidence of distant metastases.
No history of distant metastases.
Evidence of distant disease or histologically-proven nodal metastases; patients with radiologic evidence of lymphadenopathy must have biopsy proof of N status
Evidence of distant metastases
Evidence of distant metastases (below the clavicle) by clinical or radiographic examination
Prior or current evidence of any metastatic involvement of any distant site
Evidence of distant metastases
Tumors considered to be unresectable due to local advancement include an absence of distant metastases as well as:
Documented evidence of distant metastases or brain metastases
Known N nodal disease or distant metastatic disease
No evidence of distant metastatic disease
Patients with evidence of distant metastatic disease
Have distant metastases
Patients with known distant metastases or other malignancies
Patients with widespread metastatic disease (>  distant metastases); patients with oligometastatic disease (=<  distant metastases) are allowed only if they are receiving definitive (curative) radiation therapy (RT) with or without chemotherapy
Distant metastases
Radiologic evidence of distant disease
Patients with evidence of distant metastatic PDAC
Distant metastatic disease at the time of enrollment
Has distant metastases
Patients with known distant metastases or other malignancies
Patients who have prostate cancer with distant metastases
Known distant metastatic disease
No indication of distant metastases (M)
Patients have no clinical evidence of distant metastatic disease
Distant metastases
Have regional or distant metastatic disease
Clinically distant metastatic disease, either Ma/Mb/Mc
Evidence of distant disease on physical exam or initial imaging
Patients with nodal disease or distant metastatic disease
Direct evidence of regional or distant metastases after appropriate staging studies
The patient has known distant metastatic disease
Subjects with any evidence of distant metastases
